C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells

Journal of Immunology

Volumn 180, Issue 6, 2008, Pages 4316-4322

  Singh, Sanjay K ^a   Suresh, Madathilparambil V ^a   Prayther, Deborah C ^a   Moorman, Jonathan P ^a   Rusiñol, Antonio E ^a   Agrawal, Alok ^a,b  

^a East Tennessee State University   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; POLYSACCHARIDE; ETHANOLAMINE DERIVATIVE;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; FOAM CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; ATHEROSCLEROSIS; BINDING SITE; CELL CULTURE; CYTOLOGY; DENSITY GRADIENT CENTRIFUGATION; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

ATHEROSCLEROSIS; BINDING SITES; C-REACTIVE PROTEIN; CELLS, CULTURED; CENTRIFUGATION, DENSITY GRADIENT; ETHANOLAMINES; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING;

EID: 44649152987     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.6.4316     Document Type: Article

References (54)

1. Hansson, G. K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6: 508-519.
2. Ross, R. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340: 115-126.
3. Kruth, H. S. 2001. Macrophage foam cells and atherosclerosis. Front. Biosci. 6: 429-455.
4. Shrive, A. K., G. M. T. Cheetham, D. Holden, D. A. A. Myles, W. G. Turnell, J. E. Volanakis, M. B. Pepys, A. C. Bloomer, and T. J. Greenhough. 1996. Three dimensional structure of human C-reactive protein. Nat. Struct. Biol. 3: 346-354.
5. Thompson, D., M. B. Pepys, and S. P. Wood. 1999. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7: 169-177.
6. Volanakis, J. E., and M. H. Kaplan. 1971. Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136: 612-614.
7. Kushner, I., L. Rakita, and M. H. Kaplan. 1963. Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J. Clin. Invest. 42: 286-292.
8. Barrett, T. D., J. K. Hennan, R. M. Marks, and B. R. Lucchesi. 2002. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J. Pharmacol. Exp. Ther. 303: 1007-1013.
9. Pepys, M. B., G. M. Hirschfield, G. A. Tennent, J. R. Gallimore, M. C. Kahan, V. Bellotti, P. N. Hawkins, R. M. Myers, M. D. Smith, A. Polara, et al. 2006. Targeting CRP for the treatment of cardiovascular disease. Nature 440: 1217-1221.
10. Agrawal, A. 2005. CRP after 2004. Mol. Immunol. 42: 927-930.
11. Oliveira, E. B., E. C. Gotschlich, and T.-Y. Liu. 1980. Comparative studies on the binding properties of human and rabbit C-reactive proteins. J. Immunol. 124: 1396-1402.
12. Coll, J. M. 1988. Immunochemical recognition of the binding of C-reactive protein to solid-phase phosphorylethanolamine. Rev. Espanol. Fisiol. 44: 169-178.
13. Schwalbe, R. A., B. Dahlbäck, J. E. Coe, and G. L. Nelsestuen. 1992. Pentraxin family of proteins interacts specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry 31: 4907-4915.
14. Agrawal, A., M. J. Simpson, S. Black, M. P. Carey, and D. Samols. 2002. A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J. Immunol. 169: 3217-3222.
15. Taskinen, S., M. Hyvonen, P. T. Kovanen, S. Meri, and M. O. Pentikainen. 2005. C-reactive protein binds to the 3β-OH group of cholesterol in LDL particles. Biochem. Biophys. Res. Comm. 329: 1208-1216.
16. Reynolds, G. D., and R. P. Vance. 1987. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch. Pathol. Lab. Med. 111: 265-269.
17. Torzewski, M., C. Rist, R. F. Mortensen, T. P. Zwaka, M. Bienek, J. Waltenberger, W. Koenig, G. Schmitz, V. Hombach, and J. Torzewski. 2000. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 2094-2099.
18. Sun, H., T. Koike, T. Ichikawa, K. Hatakeyama, M. Shiomi, B. Zhang, S. Kitajima, M. Morimoto, T. Watanabe, Y. Asada, et al. 2005. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am. J. Pathol. 167: 1139-1148.
19. Bhakdi, S., M. Torzewski, M. Klouche, and M. Hemmes. 1999. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 19: 2348-2354.
20. Bhakdi, S., M. Torzewski, K. Paprotka, S. Schmitt, H. Barsoom, P. Suriyaphol, S. R. Han, K. J. Lackner, and M. Husmann. 2004. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 109: 1870-1876.
21. Taskinen, S., P. T. Kovanen, H. Jarva, S. Meri, and M. O. Pentikäinen. 2002. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem. J. 367: 403-412.
22. Chang, M. K., C. J. Binder, M. Torzewski, and J. L. Witztum. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA 99: 13043-13048.
23. Van Tits, L., J. de Graff, H. Toenhake, W. van Heerde, and A. Stalenhoef. 2005. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 25: 717-722.
24. Ji, S.-R., Y. Wu, L. A. Potempa, Q. Qiu, and J. Zhao. 2006. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int. J. Biochem. Cell Biol. 38: 648-661.
25. Biró, A., N. M. Thielens, L. Cervenák, Z. Prohászka, G. Füst, and G. J. Arlaud. 2006. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol. Immunol. 44: 1169-1177.
26. Rufail, M. L., S. C. Ramage, and R. van Antwerpen. 2006. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein. FEBS Lett. 580: 5155-5160.
27. De Beer, F. C., A. K. Soutar, M. L. Baltz, I. M. Trayner, A. Feinstein, and M. B. Pepys. 1982. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J. Exp. Med. 156: 230-242.
28. Nunomura, W., and M. Hatakeyama. 1990. Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Hokkaido J. Med. Sci. 65: 474-480.
29. Fu, T., and J. Borensztajn. 2002. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem. J. 366: 195-201.
30. Mookerjea, S., J. Francis, D. Hunt, C. Y. Yang, and A. Nagpurkar. 1994. Rat C-reactive protein causes a charge modification of LDL and stimulates its degradation by macrophages. Arterioscler. Thromb. 14: 282-287.
31. Zwaka, T. P., V. Hombach, and J. Torzewski. 2001. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197.
32. Verma, S., S.-H. Li, M. V. Badiwala, R. D. Weisel, P. W. Fedak, R.-K. Li, B. Dhillon, and D. A. Mickle. 2002. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896.
33. Suresh, M. V., S. K. Singh, D. A. Ferguson, Jr., and A. Agrawal. 2007. Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide. J. Immunol. 178: 1158-1163.
34. Suresh, M. V., S. K. Singh, and A. Agrawal. 2004. Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J. Biol. Chem. 279: 52552-52557.
35. Brown, A. J., S. L. Leong, R. T. Dean, and W. Jessup. 1997. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J. Lipid Res. 38: 1730-1745.
36. Klouche, M., S. Gottschling, V. Gerl, W. Hell, M. Husmann, B. Dorweiler, M. Messner, and S. Bhakdi. 1998. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler. Thromb. Vasc. Biol. 18: 1376-1385.
37. Greenspan, P., E. P. Mayer, and S. D. Fowler. 1985. Nile red: a selective fluorescent stain for intracellular lipid droplets. J. Cell Biol. 100: 965-973.
38. 125I- labeled modified C-reactive protein in CD-1 mice. Drug Metab. Dispos. 26: 977-981.
39. Labarrere, C. A., and G. P. Zaloga. 2004. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am. J. Med. 117: 499-507.
40. Verma, S., S. Devaraj, and I. Jialal. 2006. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113: 2135-2150.
41. Taylor, K. E., and C. W. van den Berg. 2007. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology 120: 404-411.
42. Pepys, M. B., P. N. Hawkins, M. C. Kahan, G. A. Tennent, J. R. Gallimore, D. Graham, C. A. Sabin, A. Zychlinsky, and J. de Diego. 2005. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res. 97: e97-e103.
43. Swafford, A. N., Jr., I. N. Bratz, J. D. Knudson, P. A. Rogers, J. M. Timmerman, J. D. Tune, and G. M. Dick. 2005. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am. J. Physiol. 288: H1786-H1795.
44. Scirica, B. M., and D. A. Morrow. 2006. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113: 2128-2134.
45. Dasu, M. R., S. Devaraj, T. W. Du Clos, and I. Jialal. 2007. Biological effects of C-reactive protein are not due to endotoxin contamination: evidence from toll-like receptor 4 knock-down human aortic endothelial cells. J. Lipid Res. 48: 509-512.
46. Liuzzo, G., M. Santamaria, L. M. Biasucci, M. Narducci, V. Colafrancesco, A. Porto, S. Brugaletta, M. Pinnelli, V. Rizzello, A. Maseri, and F. Crea. 2007. Persistent activation of nuclear factor κ-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein: evidence for a direct proinflammatory effect of azide and lipopolysaccharide- free C-reactive protein on human monocytes via nuclear factor κ-B activation. J. Am. Coll. Cardiol. 49: 185-194.
47. Doronzo, G., I. Russo, M. Trovati, and G. Anfossi. 2006. Sodium azide in commercially available C-reactive protein preparations does not influence matrix metalloproteinase-2 synthesis and release in cultured human aortic vascular smooth muscle cells. Clin. Chem. 52: 1200-1201.
48. Paul, A., K. W. Ko, L. Li, V. Yechoor, M. A. McCrory, A. J. Szalai, and L. Chan. 2004. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109: 647-655.
49. Schwedler, S. B., K. Amann, K. Wernicke, A. Krebs, M. Nauck, C. Wanner, L. A. Potempa, and J. Galle. 2005. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112: 1016-1023.
50. Hirschfield, G. M., J. R. Gallimore, M. C. Kahan, W. L. Hutchinson, C. A. Sabin, G. M. Benson, A. P. Dhillon, G. A. Tennent, and M. B. Pepys. 2005. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 102: 8309-8314.
51. Reifenberg, K., H.-A. Lehr, D. Baskal, E. Wiese, S. C. Schaefer, S. Black, D. Samols, M. Torzewski, K. J. Lackner, M. Husmann, et al. 2005. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler. Thromb. Vasc. Biol. 25: 1641-1646.
52. Trion, A., M. P. de Maat, J. W. Jukema, A. van der Laarse, M. C. Mass, E. H. Offerman, L. M. Havekes, A. J. Szalai, H. M. Princen, and J. J. Emeis. 2005. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E* 3-Leiden/human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol. 25: 1635-1640.
53. Kovacs, A., P. Tornvall, R. Nilsson, J. Tegnér, A. Hamsten, and J. Björkegren. 2007. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc. Natl. Acad. Sci. USA 104: 13768-13773.
54. Voleti, B., and A. Agrawal. 2006. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol. Immunol. 43: 891-896.